Chemed Corp. (NYSE:CHE) has received a consensus rating of “Hold” from the six research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $214.50.

CHE has been the subject of a number of research analyst reports. TheStreet cut shares of Chemed Corp. from a “b+” rating to a “c+” rating in a research note on Tuesday, July 25th. Royal Bank Of Canada reiterated a “hold” rating and issued a $209.00 target price on shares of Chemed Corp. in a research note on Friday, September 1st. KeyCorp initiated coverage on shares of Chemed Corp. in a research note on Monday, August 28th. They issued a “sector weight” rating for the company. Zacks Investment Research cut shares of Chemed Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, August 22nd. Finally, Oppenheimer Holdings, Inc. lifted their target price on shares of Chemed Corp. from $200.00 to $220.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th.

In related news, Director Patrick P. Grace sold 500 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $201.48, for a total value of $100,740.00. Following the completion of the transaction, the director now owns 4,515 shares in the company, valued at approximately $909,682.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Spencer S. Lee sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $197.46, for a total transaction of $197,460.00. Following the completion of the transaction, the insider now owns 37,809 shares of the company’s stock, valued at approximately $7,465,765.14. The disclosure for this sale can be found here. Insiders sold a total of 16,500 shares of company stock valued at $3,315,600 in the last 90 days. 5.32% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the stock. USA Financial Portformulas Corp bought a new position in Chemed Corp. in the 2nd quarter worth approximately $292,000. Dynamic Technology Lab Private Ltd bought a new position in Chemed Corp. in the 2nd quarter worth approximately $648,000. Piedmont Investment Advisors LLC bought a new position in Chemed Corp. in the 2nd quarter worth approximately $711,000. Kalos Management Inc. raised its position in Chemed Corp. by 0.7% in the 2nd quarter. Kalos Management Inc. now owns 6,521 shares of the company’s stock worth $1,333,000 after purchasing an additional 45 shares during the last quarter. Finally, Coldstream Capital Management Inc. bought a new position in Chemed Corp. in the 2nd quarter worth approximately $229,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Chemed Corp. (CHE) traded down 2.49% during mid-day trading on Monday, reaching $199.69. The company had a trading volume of 91,590 shares. The company’s 50 day moving average is $196.75 and its 200 day moving average is $197.95. Chemed Corp. has a 52-week low of $132.92 and a 52-week high of $216.01. The stock has a market capitalization of $3.19 billion, a price-to-earnings ratio of 49.54 and a beta of 1.13.

Chemed Corp. (NYSE:CHE) last posted its earnings results on Tuesday, July 25th. The company reported $2.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.89 by $0.26. Chemed Corp. had a net margin of 4.16% and a return on equity of 26.18%. The company had revenue of $415.06 million during the quarter, compared to analysts’ expectations of $407.56 million. During the same quarter in the previous year, the company posted $1.80 earnings per share. Chemed Corp.’s quarterly revenue was up 6.3% compared to the same quarter last year. Equities analysts predict that Chemed Corp. will post $8.21 earnings per share for the current year.

WARNING: “Chemed Corp. (CHE) Receives Consensus Recommendation of “Hold” from Brokerages” was first published by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/10/14/chemed-corp-che-receives-consensus-recommendation-of-hold-from-brokerages.html.

Chemed Corp. Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.